PMID- 36151562
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20221210
IS  - 1742-6405 (Electronic)
IS  - 1742-6405 (Linking)
VI  - 19
IP  - 1
DP  - 2022 Sep 23
TI  - Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs 
      in people living with HIV and concomitant colorectal cancer.
PG  - 45
LID - 10.1186/s12981-022-00470-3 [doi]
LID - 45
AB  - BACKGROUND: Previous clinical data have shown that raltegravir-based 
      antiretroviral therapy (ART) with fewer drug-drug interactions (DDIs) and adverse 
      events (AEs) is a good regimen in patients with HIV infection who need cancer 
      chemotherapy. There are currently few data on ART regimens that include Integrase 
      inhibitors (INSTIs) other than RAL among this patient subgroup. METHODS: We 
      evaluated the safety and efficacy of different kinds of INSTI-based regimens 
      among patients with HIV and concomitant colorectal cancer (CRC) who received 
      antineoplastic agents. RESULTS: From January 2020 to November 2021, 66 patients 
      were enrolled. The patients were divided into three groups: 20 patients treated 
      with dolutegravir (DTG)/lamivudine (3TC)/tenofovir (TDF) (group I), 24 patients 
      treated with DTG/albuvirtide (ABT) (group II), and 22 patients treated with 
      bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC) (group III). 
      The majority of AEs during treatment were of grade 1-2. Treatment-related AEs of 
      grade 3-4 occurred in 6 patients (9.09%), and no grade 5 AEs occurred. The most 
      common AEs were nausea (100%) and neutrophils (84.85%) attributed to anticancer 
      agents, and there was no significant difference in the incidence of these AEs 
      among the three groups (P > 0.05). Viral load rebound was not observed among 
      pretreated patients during chemotherapy. The viral load of untreated patients who 
      started their ART concomitant with chemotherapy almost decreased to the lower 
      limit of detection 6 months after ART initiation (only one patient in group III 
      had a viral load of 102 copies/ml). At the 6th month, the CD4 count in group I 
      decreased significantly from baseline (P < 0.05). However, the change in CD4 
      count was not significant in group II (P = 0.457) or group III (P = 0.748). 
      CONCLUSIONS: DTG- or BIC-containing regimens are good options for patients with 
      HIV and concomitant CRC.
CI  - (c) 2022. The Author(s).
FAU - Yang, Jing
AU  - Yang J
AD  - Department of General Surgery and Oncology Surgery, Public Health Clinical Center 
      of Chengdu, Jingju Temple 18#, Chengdu, 610066, China. Yangjingssss@163.com.
FAU - Wei, Guo
AU  - Wei G
AD  - Department of General Surgery and Oncology Surgery, Public Health Clinical Center 
      of Chengdu, Jingju Temple 18#, Chengdu, 610066, China.
FAU - Gui, Fuqiang
AU  - Gui F
AD  - Department of General Surgery and Oncology Surgery, Public Health Clinical Center 
      of Chengdu, Jingju Temple 18#, Chengdu, 610066, China.
FAU - Zhao, Yong
AU  - Zhao Y
AD  - Department of General Surgery and Oncology Surgery, Public Health Clinical Center 
      of Chengdu, Jingju Temple 18#, Chengdu, 610066, China.
FAU - Chen, Tingyu
AU  - Chen T
AD  - Department of General Surgery and Oncology Surgery, Public Health Clinical Center 
      of Chengdu, Jingju Temple 18#, Chengdu, 610066, China.
FAU - Tan, Juan
AU  - Tan J
AD  - Department of General Surgery and Oncology Surgery, Public Health Clinical Center 
      of Chengdu, Jingju Temple 18#, Chengdu, 610066, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220923
PL  - England
TA  - AIDS Res Ther
JT  - AIDS research and therapy
JID - 101237921
RN  - 0 (Amides)
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (Integrase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 43Y000U234 (Raltegravir Potassium)
RN  - 8GB79LOJ07 (bictegravir)
RN  - 99YXE507IL (Tenofovir)
RN  - G70B4ETF4S (Emtricitabine)
SB  - IM
MH  - Amides
MH  - *Anti-HIV Agents/adverse effects
MH  - *Colorectal Neoplasms/chemically induced/complications/drug therapy
MH  - Emtricitabine/adverse effects
MH  - *HIV Infections/complications/drug therapy
MH  - Heterocyclic Compounds, 3-Ring/therapeutic use
MH  - Heterocyclic Compounds, 4 or More Rings/therapeutic use
MH  - Humans
MH  - Integrase Inhibitors/therapeutic use
MH  - Lamivudine/adverse effects
MH  - Piperazines
MH  - Pyridones
MH  - Raltegravir Potassium/adverse effects
MH  - Tenofovir/adverse effects
PMC - PMC9508721
OTO - NOTNLM
OT  - Adverse events (AEs)
OT  - Antiretroviral therapy (ART)
OT  - Colorectal cancer (CRC)
OT  - Human immunodeficiency virus (HIV)
OT  - Integrase inhibitors (INSTIs)
COIS- The authors declare no competing interests. The authors declare no competing 
      interests.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/28 06:00
PMCR- 2022/09/23
CRDT- 2022/09/23 23:44
PHST- 2022/06/22 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/09/23 23:44 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/23 00:00 [pmc-release]
AID - 10.1186/s12981-022-00470-3 [pii]
AID - 470 [pii]
AID - 10.1186/s12981-022-00470-3 [doi]
PST - epublish
SO  - AIDS Res Ther. 2022 Sep 23;19(1):45. doi: 10.1186/s12981-022-00470-3.